David Raben
Known title: Chief Medical OfficerCIK: 0002034679
Associated companies
Transaction History
| BCAX | ▲ Buy | Option Exercise | 5,500 | $21K | 4/27/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 5,500 | $126K | 4/27/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 5,500 | $21K | 3/25/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 5,500 | $104K | 3/25/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 16,300 | $62K | 3/4/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 16,300 | $302K | 3/4/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 200 | $758 | 3/3/2026 | View on chart |
| BCAX | ▼ Sell | Open Market | 200 | $4K | 3/3/2026 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 19,789 | $75K | 12/26/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 4,594 | $17K | 11/25/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 4,594 | $87K | 11/25/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 906 | $3K | 11/25/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 906 | $17K | 11/25/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 5,500 | $21K | 11/24/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 5,500 | $101K | 11/24/2025 | View on chart |
| BCAX | ▲ Buy | Option Exercise | 22,000 | $83K | 10/9/2025 | View on chart |
| BCAX | ▼ Sell | Open Market | 22,000 | $406K | 10/9/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
BCAX flagged as potentially overvalued on book value
A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.
BCAX flagged as potentially overvalued on book value. A recent analysis suggests Bicara Therapeutics stock may be overvalued when compared to its book value. This valuation concern is notable given that the stock is currently trading near its 52-week low and has an RSI of 30.1, indicating it is in oversold territory. While the average analyst target is $35.50, the wide range of estimates reflects significant uncertainty about the company's future performance.